The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

MSD has received the UK MHRA approval for sotatercept, marketed as Winrevair, to treat PAH in the adult population.

HUTCHMED (China) has entered into agreements to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals (SHPL) ...

Explore how strategic intelligence agencies and competitive intelligence solutions are shaping the pharmaceutical industry. Download our guide to technological advancements and more invaluable ...

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that ...

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.